{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:01:03Z","timestamp":1789876863710,"version":"4.0.1"},"reference-count":35,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0569","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:08:38Z","timestamp":1767823718000},"page":"n\/a","source":"Crossref","is-referenced-by-count":2,"title":["A Case of Pathological Complete Response after \u201cConversion Surgery\u201d for Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma"],"prefix":"10.70352","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4587-9334","authenticated-orcid":false,"given":"Yasunori","family":"Shirakawa","sequence":"first","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6518-2077","authenticated-orcid":false,"given":"Tomoaki","family":"Yoh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-8317","authenticated-orcid":false,"given":"Takashi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-330X","authenticated-orcid":false,"given":"Satoshi","family":"Ogiso","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-9653","authenticated-orcid":false,"given":"Takamichi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-6507","authenticated-orcid":false,"given":"Masakazu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-9561","authenticated-orcid":false,"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-1918","authenticated-orcid":false,"given":"Etsuro","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 2019; 71: 104\u201314.","DOI":"10.1016\/j.jhep.2019.03.013"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol 2023; 79: 181\u2013208.","DOI":"10.1016\/j.jhep.2023.09.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 2016; 23: 235\u201343.","DOI":"10.1245\/s10434-015-4642-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 2023; 30: 102\u201310.","DOI":"10.1002\/jhbp.1219"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 1853\u201365.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Oh DY, He AR, Bouattour M, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol 2024; 9: 694\u2013704.","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Sumiyoshi T, Uemura K, Shintakuya R, et al. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Clin J Gastroenterol 2022; 15: 1164\u20138.","DOI":"10.1007\/s12328-022-01700-x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shimamaki Y, Hosokawa I, Takayashiki T, et al. Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma. Surg Case Rep 2024; 10: 35.","DOI":"10.1186\/s40792-024-01832-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84\u201396.","DOI":"10.1097\/SLA.0b013e318176c4d3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 2018; 105: 839\u201347.","DOI":"10.1002\/bjs.10641"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Nakamura I, Hatano E, Baba H, et al. Impact of conversion surgery after chemotherapy in patients with initially unresectable and recurrent biliary tract cancer. Ann Gastroenterol Surg 2023; 7: 1009\u201320.","DOI":"10.1002\/ags3.12713"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yabushita Y, Park JS, Yoon Y-S, et al. Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea. J Hepatobiliary Pancreat Sci 2024; 31: 481\u201391.","DOI":"10.1002\/jhbp.1437"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zhou Y, Wang Q, Lin M, et al. Survival benefit of conversion surgery for initially unresectable biliary tract cancer: a systematic review and meta-analysis. Langenbecks Arch Surg 2025; 410: 63.","DOI":"10.1007\/s00423-025-03630-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) D\u2019Alessio A, Stefanini B, Blanter J, et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol 2024; 25: 1465\u201375.","DOI":"10.1016\/S1470-2045(24)00457-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zeng Z-X, Wu J-Y, Wu J-Y, et al. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer 2024; 13: 498\u2013508.","DOI":"10.1159\/000536376"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 2023; 73: 198\u2013222.","DOI":"10.3322\/caac.21759"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273\u201381.","DOI":"10.1056\/NEJMoa0908721"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nagino M, Hirano S, Yoshitomi H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci 2021; 28: 26\u201354.","DOI":"10.1002\/jhbp.870"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022; 33: 929\u201338.","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019; 7: 306.","DOI":"10.1186\/s40425-019-0805-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Das S, Ciombor KK, Haraldsdottir S, et al. Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration-approved indications for immunotherapy. Oncologist 2020; 25: 669\u201379.","DOI":"10.1634\/theoncologist.2019-0637"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 2015; 26: 1813\u201323.","DOI":"10.1093\/annonc\/mdv209"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primary nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol 2007; 5: 36.","DOI":"10.1186\/1477-7819-5-36"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tran TB, Bal CK, Schaberg K, et al. Locally advanced intrahepatic cholangiocarcinoma: complete pathologic response to neoadjuvant chemotherapy followed by left hepatic trisectionectomy and caudate lobectomy. Dig Dis Sci 2015; 60: 3226\u20139.","DOI":"10.1007\/s10620-015-3640-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 2015; 22: 1093\u20139.","DOI":"10.1245\/s10434-015-4768-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Matsubara T, Nishida T, Tomimaru Y, et al. Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine\/cisplatin\/S-1 combination chemotherapy: a case report. Mol Clin Oncol 2016; 5: 757\u201361.","DOI":"10.3892\/mco.2016.1065"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Tatsuguchi T, Gotoh K, Kobayashi S, et al. Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma. Int Cancer Conf J 2018; 7: 93\u20137.","DOI":"10.1007\/s13691-018-0327-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Abudalou M, Vega EA, Kondratiev S, et al. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus 2021; 13: e20187.","DOI":"10.7759\/cureus.20187"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Li X, Jiang Z, Wu Y, et al. Case report: conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel. Front Oncol 2022; 12: 935817.","DOI":"10.3389\/fonc.2022.935817"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Zhang X, Tang H, Fan J, et al. Case report: a report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Front Immunol 2022; 13: 1051130.","DOI":"10.3389\/fimmu.2022.1051130"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Robinson MD, Wheatley R, Foster L, et al. Intrahepatic cholangiocarcinoma with extrahepatic metastasis and high tumor mutation burden: case of complete pathological response to cisplatin\/gemcitabine\/pembrolizumab. JCO Precis Oncol 2024; 8: e2300572.","DOI":"10.1200\/PO.23.00572"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Fukuda K, Kasuga A, Shigematsu Y, et al. Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency. Clin J Gastroenterol 2025; 18: 520\u20136.","DOI":"10.1007\/s12328-025-02122-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 127\u201340.","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Huppert LA, Wolf D, Yau C, et al. Pathologic complete response (pCR) rates for patients with HR+\/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol 2025; 36: 172\u201384.","DOI":"10.1016\/j.annonc.2024.10.018"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0569\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:46:46Z","timestamp":1768020406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0569\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0569","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0569"}}